February 12, 2008 - Positron emission tomography (PET) was far more reliable than computed tomography (CT) in detecting whether or not a nodule was malignant, according to findings in a large, multi-institutional study comparing PET and CT in their accuracy in the characterization of lung nodules.

The researchers found that when PET and CT results were interpreted as "probably" or "definitely" benign, the results were "strongly associated with a benign final diagnosis," therefore, the modalities were equally good at making this determination. PET’s superior specificity (accuracy in characterizing a nodule as benign or malignant), however, resulted in correctly classifying 58 percent of the benign nodules that had been incorrectly classified as malignant on CT. Furthermore, when PET interpreted SPNs as definitely malignant, a malignant final diagnosis was 10 times more likely than a benign.

"CT and PET have been widely used to characterize solitary pulmonary nodules (SPNs) as benign or malignant," said James W. Fletcher, professor of Radiology at Indiana University School of Medicine in Indianapolis, IN. "Almost all previous studies examining the accuracy of CT for characterizing lung nodules, however, were performed more than 15 years ago with outdated technology and methods, and previous PET studies were limited by small sample sizes."

"Detecting and characterizing SPNs is important because malignant nodules represent a potentially curable form of lung cancer. Identifying which SPNs are most likely to be malignant enables physicians to initiate the proper therapy before local or distant metastases develop," said Fletcher.

In a head-to-head study addressing the limitations of previous studies, PET and CT images on 344 patients were independently interpreted by a panel of experts in each imaging modality, and their determination of benign and malignant nodules were compared to pathologic findings or changes in SPN size over the next two years.

SPNs are commonly encountered in both primary and specialty settings, often showing up on chest X-rays obtained for some other purpose than cancer screening and are often the first manifestation of lung cancer. The question for these patients then becomes whether to undergo surgery, undergo a needle biopsy or "watch and wait" to find out if the nodule is benign or malignant but treatable.

“In patients with an untreated and undiagnosed SPN between 7 and 30 millimeters, PET provides better identification of malignant nodules that require a more aggressive treatment approach,” said Fletcher. “PET in combination with CT can also provide good identification of those nodules that are most likely to be benign, suggesting that a ‘watch and wait’ strategy can be adopted in lieu of unnecessary invasive - and expensive - procedures such as needle biopsy or surgery,” he added.

For more information: http://www.snm.org


Related Content

News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
Subscribe Now